157 related articles for article (PubMed ID: 17415408)
1. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria.
Malkin E; Long CA; Stowers AW; Zou L; Singh S; MacDonald NJ; Narum DL; Miles AP; Orcutt AC; Muratova O; Moretz SE; Zhou H; Diouf A; Fay M; Tierney E; Leese P; Mahanty S; Miller LH; Saul A; Martin LB
PLoS Clin Trials; 2007; 2(4):e12. PubMed ID: 17415408
[TBL] [Abstract][Full Text] [Related]
2. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01.
Otsyula N; Angov E; Bergmann-Leitner E; Koech M; Khan F; Bennett J; Otieno L; Cummings J; Andagalu B; Tosh D; Waitumbi J; Richie N; Shi M; Miller L; Otieno W; Otieno GA; Ware L; House B; Godeaux O; Dubois MC; Ogutu B; Ballou WR; Soisson L; Diggs C; Cohen J; Polhemus M; Heppner DG; Ockenhouse CF; Spring MD
Malar J; 2013 Jan; 12():29. PubMed ID: 23342996
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults.
Ellis RD; Martin LB; Shaffer D; Long CA; Miura K; Fay MP; Narum DL; Zhu D; Mullen GE; Mahanty S; Miller LH; Durbin AP
PLoS One; 2010 Jan; 5(1):e8787. PubMed ID: 20107498
[TBL] [Abstract][Full Text] [Related]
4. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers.
Huaman MC; Martin LB; Malkin E; Narum DL; Miller LH; Mahanty S; Long CA
J Immunol; 2008 Feb; 180(3):1451-61. PubMed ID: 18209040
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
[TBL] [Abstract][Full Text] [Related]
7. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
Darko CA; Angov E; Collins WE; Bergmann-Leitner ES; Girouard AS; Hitt SL; McBride JS; Diggs CL; Holder AA; Long CA; Barnwell JW; Lyon JA
Infect Immun; 2005 Jan; 73(1):287-97. PubMed ID: 15618165
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.
Ellis RD; Wu Y; Martin LB; Shaffer D; Miura K; Aebig J; Orcutt A; Rausch K; Zhu D; Mogensen A; Fay MP; Narum DL; Long C; Miller L; Durbin AP
PLoS One; 2012; 7(10):e46094. PubMed ID: 23056238
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.
Mullen GE; Giersing BK; Ajose-Popoola O; Davis HL; Kothe C; Zhou H; Aebig J; Dobrescu G; Saul A; Long CA
Vaccine; 2006 Mar; 24(14):2497-505. PubMed ID: 16434128
[TBL] [Abstract][Full Text] [Related]
10. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses.
Lyon JA; Angov E; Fay MP; Sullivan JS; Girourd AS; Robinson SJ; Bergmann-Leitner ES; Duncan EH; Darko CA; Collins WE; Long CA; Barnwell JW
PLoS One; 2008 Jul; 3(7):e2830. PubMed ID: 18665258
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
Mullen GE; Ellis RD; Miura K; Malkin E; Nolan C; Hay M; Fay MP; Saul A; Zhu D; Rausch K; Moretz S; Zhou H; Long CA; Miller LH; Treanor J
PLoS One; 2008 Aug; 3(8):e2940. PubMed ID: 18698359
[TBL] [Abstract][Full Text] [Related]
13. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
Ntege EH; Arisue N; Ito D; Hasegawa T; Palacpac NMQ; Egwang TG; Horii T; Takashima E; Tsuboi T
Vaccine; 2016 Nov; 34(46):5612-5622. PubMed ID: 27692771
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
15. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
[TBL] [Abstract][Full Text] [Related]
16. Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria.
Spring MD; Chelimo K; Tisch DJ; Sumba PO; Rochford R; Long CA; Kazura JW; Moormann AM
Infect Immun; 2010 Oct; 78(10):4431-41. PubMed ID: 20696832
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children.
Dicko A; Sagara I; Ellis RD; Miura K; Guindo O; Kamate B; Sogoba M; Niambelé MB; Sissoko M; Baby M; Dolo A; Mullen GE; Fay MP; Pierce M; Diallo DA; Saul A; Miller LH; Doumbo OK
PLoS One; 2008 Feb; 3(2):e1563. PubMed ID: 18270560
[TBL] [Abstract][Full Text] [Related]
19. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
